Summary & Overview
HCPCS G0432: HIV-1/HIV-2 Antibody Screening by EIA
HCPCS Level II code G0432 represents an enzyme immunoassay (EIA) screening test for antibodies to HIV-1 and/or HIV-2. As a routine laboratory screening pathway, this code supports public health efforts to identify HIV infection early and guide linkage to care. Nationally, HIV screening remains a priority for prevention and early treatment, and G0432 is used in ambulatory and community settings where specimens are collected and analyzed in clinical laboratories.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, common billing and coverage patterns across major payers, and the contexts in which G0432 is typically reported. The publication also summarizes benchmarks and policy considerations relevant to laboratory screening for HIV, notes common modifier usage where applicable, and outlines typical sites of service and clinical scenarios for reporting this code.
Data not available in the input is noted where payer-specific rates, associated taxonomies, and precise ICD-10 mappings are not provided.
Billing Code Overview
HCPCS Level II code G0432 describes infectious agent antibody detection by enzyme immunoassay (EIA) technique for HIV-1 and/or HIV-2, screening. This service is a laboratory screening test that detects antibodies to HIV-1 and HIV-2 using an enzyme immunoassay method.
-
Service type: Laboratory diagnostic screening test
-
Typical site of service: Clinical laboratory, outpatient clinic, community health center, or other ambulatory care settings where specimen collection and laboratory testing occur
Clinical & Coding Specifications
Clinical Context
A 28-year-old sexually active patient presents to a primary care clinic requesting routine screening for HIV. The clinician documents sexual history and risk assessment, obtains informed consent, and collects a venous blood specimen. The specimen is sent to the laboratory where an enzyme immunoassay (EIA) for HIV-1 and/or HIV-2 antibodies is performed using an automated platform. Negative EIA results are reported to the ordering provider and patient with routine counseling. Reactive or repeatedly reactive EIA results trigger reflex confirmatory testing per laboratory protocol (e.g., HIV-1/HIV-2 differentiation immunoassay or HIV-1 RNA testing). Typical workflow steps: patient encounter and order entry, specimen collection and labeling, transport to clinical laboratory, performance of G0432 test, result verification by laboratory personnel, reporting to provider, and follow-up counseling or confirmatory testing as indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when only the professional component (interpretation) is billed separately from the technical component. |
TC |